{"name":"Nerviano Medical Sciences","slug":"nerviano-medical-sciences","ticker":"","exchange":"","domain":"nervianomedicalsciences.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQY0EyRFZ3NjVXbWN2Mzh2aDNJZS1GR3pmR3d4VHd1MUxMVElCb21LYjdUQjctZUcyQ1NJY1BKWldKVkpnZVRVMVhHZVRhUVViZHAyejBtMnRxSlFlV0xfaGdhVC0wd2huQi13Tk5uUGpjWGFkX1pHNGVHWDF2UnFQdUdmVF9WSHowcVlab1ZJbUxvSFBKcWc?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Glioma Pipeline Expands as 180+ Pharma Companies Advance - openPR.com","headline":"Glioma Pipeline Expands as 180+ Pharma Companies Advance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxQOGdNMTN1RElfTmhkU0xLTTZlV3Z4OTNEUjFyYjJLNzVjaFdUbDVHSjFrUXREZjAyLXF5clh4Q2x4U29Eb2loQkttODdYOVlUd2hFZkxPOEJDV0xIdEQ1OGZEaUQxMHVCR09NLS1Cd19QS0JxX3M5Q1I2RGtHQUpxTlZ2ZGpvUTNJdVo5ejQ5MGktaC1fdE85MnliWVc5eHpwdnZyMXhQU1d5N01MX3ItZktMLTd0bW5fcTVxNDVOeU44YnFSd3FjVWt6LXhhcXRadnAtRGlNYTR4MmlQbkNaY01fZTJLek1vWXdfRzZxV1FKSVNXV0RwbThRR21NNUlwbFExSG9CVnhuLVhiZFlkWHYwYXdJQzR3SGZSQzl6MS1HRjVZOTNKTTVzdm1RTmRwRVc0MWdrMTVMa2RQRTFaSlZncFNKVGJBYS1ibzdBNHI?oc=5","date":"2026-03-19","type":"pipeline","source":"Barchart.com","summary":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Bar","headline":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5GTHhiX3NjNnk2dU80ejNRTE1hMVZtZG1felBhYTBNSm9vV2xhZzhGdjl2U1Q0cmlqeFc1VnpkODNyaW8yM29XaXBXUmZTMkQxZTdnY1pmR1dzYzRw?oc=5","date":"2025-08-08","type":"pipeline","source":"EurekAlert!","summary":"Reducing the global burden of liver cancer: Recommendations from The Lancet commission - EurekAlert!","headline":"Reducing the global burden of liver cancer: Recommendations from The Lancet commission - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOLXMtZlFJTmRmZVZ4YXA5bEdrVHpwTXMzR1VJallzekU0ZXhmUERqOTctUzh1b3FycmM2Ul9hSDYyUF9lSDZheDh6RTc3ZWF6WXlYaWpSZlFtc01IbFRvX3FLeVVqNzFDZmh1elZwR2F2QmR4RUh4WlJFWEQ1X3dGR3J3bTJ4Q2xkOHZXdVFRbE1rVzU3WktXRlE3T1RJUXQ3UUVmcXJMRUswYlYwRmVhM3JWekUxWWp6RnhTLVA3Rm1NSUJlM2pDclpFbThVMDFrOTFzeWUtaDMtVWFsZkdoMUVyVHpEdTVRakVwbFl6SXMwYjZUS3FRR04xYnNWMEk?oc=5","date":"2025-03-24","type":"pipeline","source":"PR Newswire UK","summary":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight - PR Newswire UK","headline":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-08-13","type":"trial","source":"GlobeNewswire","summary":"Chronic Myelomonocytic Leukemia Clinical Trial Pipeline - GlobeNewswire","headline":"Chronic Myelomonocytic Leukemia Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOLVhTLXdyeWkxMHJxejd5MVd6X2hnekxMQVF3QnVTRXBJN3RBSS0wUzEzNEkxNm5mdVpJbzJsTmx0NUt5eWp2Y01ORVE1WHI2SERXM0RYOVZGWkpNSEUtdXdwY1NBR3VFOS10ZGNQa01SRW56ODdhelZZVE00ZVFwanpOQnJpWnZxajJoTzhnYlhCOVNwN2J4YzJwWXhvck9EcVdWelgwSWx4QkpZSXlJNw?oc=5","date":"2024-01-24","type":"trial","source":"Fierce Biotech","summary":"Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs - Fierce Biotech","headline":"Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNaXRUSVVPS3U4ZHNGQV96U2xFMVQzUnQxRFlUOU1RbTVPaWVnUE9sWnVLb2FGd04wQ2ZFU2dRVUNqUEYyeFJ3c3REMENsSlJWNEZDcmI0WFpoLS1ZRDB4QVlYSXNmZUlva1VuMmlKaE5uOWFOaU5maVYtd2l6eEtKNmRQcmZTVXZYdDZCcEM0UkdNMzhWS0dOZUg5RUU?oc=5","date":"2023-12-14","type":"deal","source":"Contract Pharma","summary":"Nerviano Medical Sciences, Italfarmaco Partner on Novel PDC - Contract Pharma","headline":"Nerviano Medical Sciences, Italfarmaco Partner on Novel PDC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxPSmRVZXNJaENtcE5zb3RBUHA5NmZDa0RGVUpZMXUzdkEzSkU2WXdOVUt2SDZOelpMT3dqdUhnN1dnVHJOUDZWTkJVa250aE9VaEd1OFlWbFJ0a3hvbWZjRXFZSjhaOEctZWN4RUlZMHpyakdETXV6ZmsyRzJDVlROeEltYjlSLVJvdEZ0eDh1eUNJTEZiaFlKb3FXeXlVVTJfTWxmdFF4Tm1EUVoxd29ndEV6X21xOG1BRFdOY3I2U2owN1JnRHQxbzJTbFR0akZjcldadm5wV1Q0Zmg1emJCM3g3WGxJZVAzZEc1V2Mxa1B2MFFlQUY1RF9GY3BGNEVPRjRGRU5TaXg4aXNnX1Q1UXUxVmExOUQxcGFQVTY4eHRDemgweEtUNGZFN3pYeGM?oc=5","date":"2023-12-14","type":"pipeline","source":"Business Wire","summary":"Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate - Business Wire","headline":"Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWjltQUxBV095SUpoSVUtenZJSHlBQUhwa1FHQ1czXzJ6emktVDhjYmpxOXJsZ1ZVWk1HcEdBdzBFTTBRWFN3UFpPV18zaVV1NmdGSGdmRVdET0RRRU9xSEUxTGRnbXRqRXQxRDkzS1FtZlVTRUl4WUdNdVZVSmgxanVGbDFEWWVWRVp3?oc=5","date":"2023-07-01","type":"pipeline","source":"Frontiers","summary":"ALK Inhibitors, a Pharmaceutical Perspective - Frontiers","headline":"ALK Inhibitors, a Pharmaceutical Perspective","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBrNFZjZHU4QmhlVmhybU9iQlA0UldaR3c0Qk1QSnJFaXMyTTkxMWlEMDZWYlRGdmpxTElFYW5BZVE2Yl9WQmhwdU5UMmVuUnFIbmZTUnNxV2ZaaGdZMFhoVHVSZHltakZm?oc=5","date":"2023-01-23","type":"pipeline","source":"Straits Research","summary":"FLT3 Inhibitors Market Size, Top Share, Report to 2033 - Straits Research","headline":"FLT3 Inhibitors Market Size, Top Share, Report to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPaTV0VFJDMHZrVm1HMXVuemc3UEUxNDBjRHcyRVdVbjIwc0JFZnZka1VjSF9IM1pzSk9JM1dJbEtLOS05eEJWVUwzWE1PeVBXUXVFTXpxeG5TMFJsT2hZN1l5NU5kVVFzdml4Sjl0a1dfa0VmZVEweElqTUd4U2hvMFQtWWlFUzBlMnFHc3dwalVtaTdqN282Uml4RTk5OExUUDBMblNvX2JHSlBBV1U4SWttanFabVJ4azNfUWg5Tm5la0NjRG5oUUdldjFfSDlqbDJEWmVhbjhfY1VHaXBPLVRscDF3RjJiSEpfN19mQVpLZUN4TUtaLTRUS2xIQ1lxZ1owLUtOelludjhnczVvX0Uxa2I0RndBd2s3c3cxbGhZSEVZUGc?oc=5","date":"2022-09-21","type":"deal","source":"Business Wire","summary":"Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor - Business Wire","headline":"Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PAR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQMXFyU0FSV1lhYjdpNFZvMllMdGU5eE9Mc2JVZGZtekJjajhWRkRKdzdwVzVqanFmM3FkTUt2b2gwUE1OSlMwYzBRYVQxdzBTaTV4VktDa1pWZWRCNGlfalZGYk9QcGJXaTlaQ1cwOWI0Z1RhUjR5Yl9la0NXWHlkZjVNNThjXzhLMEhNUlBZMkdGaTdrcTljeVJpSGZ1dWZwX2hkUVBqcGR0Nmk0MWZxaWhXSnMtSGVzS20xbjlISGJFSU1ocHhYdHN1WDJCdVRYOWZQSllMdHlNYldYQ2FFZUUxSHY5SDhI?oc=5","date":"2017-12-28","type":"pipeline","source":"BioSpace","summary":"Shanghai’s SARI Pays $359M for Italian Cancer Biopharma NMS - BioSpace","headline":"Shanghai’s SARI Pays $359M for Italian Cancer Biopharma NMS","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}